Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at B. Riley issued their Q1 2026 EPS estimates for TG Therapeutics in a research note issued to investors on Tuesday, November 4th. B. Riley analyst W. Wood expects that the biopharmaceutical company will earn $0.45 per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.46 EPS and Q4 2026 earnings at $0.52 EPS.

Several other analysts have also recently issued reports on TGTX. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. HC Wainwright started coverage on shares of TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

TG Therapeutics Stock Up 0.7%

TGTX stock opened at $34.04 on Wednesday. The stock has a market capitalization of $5.40 billion, a P/E ratio of 92.00 and a beta of 1.97. The firm has a 50-day simple moving average of $33.77 and a 200-day simple moving average of $34.74. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company’s revenue was up 92.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently bought and sold shares of TGTX. State Street Corp boosted its stake in shares of TG Therapeutics by 2.5% in the second quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after purchasing an additional 184,339 shares during the period. Geode Capital Management LLC raised its holdings in shares of TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after purchasing an additional 207,890 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after acquiring an additional 345,059 shares during the period. Hood River Capital Management LLC increased its holdings in shares of TG Therapeutics by 0.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock worth $56,415,000 after acquiring an additional 11,018 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of TG Therapeutics by 1,809.9% in the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock worth $47,830,000 after acquiring an additional 1,149,526 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.64% of the stock is currently owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.